Figure 1.
Ratio of the annual rate of clinically significant exacerbations with mepolizumab 100 mg SC versus placebo by baseline biomarker and PBEC subgroup. CI, confidence interval; ECP, eosinophil cationic protein; EDN, eosinophil‐derived neurotoxin; PBEC, peripheral blood eosinophil count; SC, subcutaneous